A Dose-escalation Study in Subjects With Advanced Malignancies

Phase 1CompletedNCT01195311

Incyte Corporation52 enrolled

Overview

This is an open label, dose escalation study using a 3 + 3 design to determine if INCB024360 (study drug) is safe, well-tolerated and effective in patients with advanced malignancies. Patients will be enrolled and treated in cohorts of three and each observed a minimum of 28 days before the next group is enrolled and may begin to receive study drug. For subject safety, the first subject in each cohort will be administered drug for one week before the next two subjects in the cohort can begin drug administration. Doses will be escalated unless a dose-limiting toxicity (DLT) is observed in one of three subjects. An expanded cohort of up to 15 patients may be recruited to further explore safety at the 'maximum tolerated dose' or at a lower, pharmacologically active, dose.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Solid Tumors and Hematologic Malignancy

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with neoplastic disease refractory to currently available therapies or for which no effective treatment is available * Subjects with life expectancy of 12 weeks or longer. * Subjects with Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2. Exclusion Criteria: * Subjects who received any anti-cancer medications in the 21 days prior to receiving their first dose of study medication or 6 weeks for mitomycin-C or nitrosoureas. * Subjects with history of brain metastases or spinal cord compression. * Subjects who have undergone a bone marrow or solid organ transplant. * Subjects who have had major surgery within 4 weeks prior to study entry or had minor surgical procedure within 7 days prior to initiating treatment. * Subjects with a history of any gastrointestinal condition * Is receiving any compound that is known to be a potent inducer or inhibitor of CYP3A4 * Subjects with an active autoimmune process or is receiving therapy for an autoimmune disease * Subjects treated with a serotonin reuptake inhibitor within 3 weeks prior to study entry

Locations (2)

Unnamed facility

Chicago, Illinois, United States

Unnamed facility

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Safety and tolerability as measured by adverse events and dose limiting toxicities

Time frame: Measured from baseline through follow-up period (measured during cycle 1 weekly and bi monthly thereafter)

Secondary Outcomes

Tumor assessment as measured by RECIST criteria

Time frame: Measured from baseline through treatment cessation. (Measured every other cycle and end of study)

Measurement of IDO inhibition in whole blood measured through blood sampling.

Time frame: Cycle 1, Day 1 and each 28 day subsequent cycle at Day 1

PK analysis

Time frame: Full PK at Days 1, 8 (trough only), 15 at Cycle 1 and trough at each subsequent cycle at Day 1